Most patients with advanced NSCLC have EGFR mutations and receive first-line standard treatment with EGFR TKIs, such as erlotinib, gefitinib, icotinib, afatinib, dacomitinib, and osimertinib [7]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.